1225 / 1816
Tole
rance of the
Ra
diotherapy of BC
associated or not with
B
evacizumab
ToleRAB:
National retrospective case-controls study
•
Patients includes in the adjuvant studies with bevacizumab as BEATRICE
or neo adjuvant (BEVERLY) associated with radiotherapy (RT) in the breast
cancer (BC) treatment
•
Follow-up of two cohorts: +/- Bevacizumab during 5 years after the end of
the RT
•
65 patients included in the cohort bevacizumab
•
62 patients evaluated at 1 year